ClinicalTrials.gg
RecruitingNCT07857733Updated Oct 16, 2026

Phase 3, Open-Label Extension Study of AMBTX-01 (Neridronate) for Complex Regional Pain Syndrome Type 1

A Phase 3 interventional study of Neridronate in Complex Regional Pain Syndrome Type I, sponsored by Ambros Therapeutics, Inc.. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Ambros Therapeutics, Inc. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Oct 16, 2026Now RecruitingFirst site in United States+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
135
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 88 studies in Complex Regional Pain Syndromes with a site in United States — 20 open to participants now, 22 under way, 2 of them phase 3. Complex Regional Pain Syndromes · United States.

Planned enrollment
10th of 67
135 · median 30
Started
2026
with 5 others
Phase 3
12 of 88
2 open now
Primary completion
2028-12
later than 18 of 21 live
Registered
88th of 88
by date
Lead sponsor
3 of 88
Ambros Therapeutics, Inc.

Among the 88 studies in Complex Regional Pain Syndromes with a site in United States, this one is the 10th largest by planned enrollment of the 67 interventional ones that give a count, is one of 6 that started in 2026, is one of 12 in phase 3, reaches primary completion later than 18 of the 21 other live ones, and was the 88th registered.

Complex Regional Pain Syndromes

206 studies on the registry are indexed under Complex Regional Pain Syndromes; 54 are open to participants now.

Browse Complex Regional Pain Syndromes studies →

Open to participants now

20 of the 88 studies in Complex Regional Pain Syndromes with a site in United States are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 39 Complex Regional Pain Syndromes studies recruiting now, 17 (44%) set no upper age limit and 16 (41%) stop at 75 or younger; 3 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 88 studies in Complex Regional Pain Syndromes with a site in United States, or all of them as a file.
02

Study summary

A Phase 3 open-label extension study of AMBTX-01 (neridronate) for Complex Regional Pain Syndrome Type 1

Read the detailed description

This is a multicenter, open-label extension study to assess the safety, tolerability, and efficacy of IV neridronate 400 mg in eligible participants who have completed the Phase 3 AMBTX-01-301 Randomized Clinical Trial.

The total planned trial duration for each participant will be approximately up to 24 weeks and will include:

  • Screening period of up to 12 weeks
  • Treatment period on Days 1, 4, 7, and 10
  • Post-treatment follow-up through Week 12
03

Conditions studied

  • Complex Regional Pain Syndrome Type I

Keywords

  • CRPS-1
  • Pain
  • edema
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants must have completed the Week 12 visit of the neridronate AMBTX-01-301 Randomized Clinical Trial (RCT).
  2. Both the Investigator and participant must agree that the participant is reasonably likely to benefit from neridronate therapy without undue risk based on information about benefits/risks in the IB.
  3. The Investigator must characterize the participants CRPS-1 as a serious condition based on the presence of persistent moderate-to-severe pain or/and persistent moderate-to-severe CRPS-1 signs or/and symptoms other than pain.
  4. Participants must be capable of understanding the study requirements and willing to provide prior to any study-related procedures.
  5. Participants must be willing and able to comply with the scheduled treatment plan including 4 infusion visits and safety-related assessments.
  6. Participants must have adequate venous access to enable blood sampling and 4 IV infusions.
  7. Women of must:

    1. Be nonpregnant as determined by a negative highly sensitive urine pregnancy test on every visit before neridronate administration.
    2. Be nonlactating.
    3. Agree to use a highly effective method of from at least 28 days prior to treatment for oral contraception (or at least 1 week longer than specified by the manufacturer for other contraceptives) and for at least 6 months following last neridronate administration.

Exception: Women exclusively engaging in same sex sexual activities are not required to meet this criterion.

Exclusion criteria

Exclusion Criteria:

  1. Individuals who did not participate in AMBTX-01-301 RCT, or those participants from AMBTX-01-301 RCT who discontinued product and/or were withdrawn from the trial.
  2. Evidence of severely impaired renal function .
  3. Prior or planned renal transplant.
  4. The use of any of the following treatments within the timeframe specified from initiation of treatment with neridronate and through the study:

    1. Within the last 12 months - IV immunoglobulin, any IV bisphosphonates (excluding investigational product as part of AMBTX-01-301 RCT prior to open-label treatment);
    2. Within the last 6 months: Any oral bisphosphonate, denosumab (Prolia®) or receptor activator of nuclear factor kappa B ligand (RANKL) inhibitors (e.g., denosumab biosimilar compounds), Calcitonin, ketamine, Radiation therapy to the head or neck;
    3. Within the last 3 months: Cinacalcet, Monoclonal antibody peptides against calcitonin gene-related peptide (CGRP), spinal cord stimulation, radiofrequency ablation, peripheral nerve stimulation and other procedural forms of neuromodulation
    4. Within the last 1 month - Any systemic (intranasal, inhaled, or topical corticosteroids are acceptable)
    5. Within 2 weeks - Lidocaine infusion, somatic or sympathetic nerve blocks, acupuncture, electromagnetic field treatment, scrambler therapy, dorsal root ganglia (DRG) block, initiation or implementation of radiofrequency ablation or other sympathectomy procedures
  5. Hypocalcemia, or high risk for hypocalcemia
  6. Vitamin D deficiency
  7. Serum potassium or magnesium outside of the laboratory's reference range at Screening
  8. Elevated liver-related lab tests or evidence of significant liver disease
  9. Significant dental findings.
  10. Eye inflammation
  11. Clinically unstable cardiac disease
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
135 participants (estimated)

Study arms

  • Experimental
    Neridronate

    400 mg AMBTX-01 infusion

    Drug: Neridronate

Interventions

  • 100 mg, given as a 2-hour infusion on Days 1, 4, 7, and 10.

06

What researchers measure

Primary outcomes

  1. Number of Participants with Treatment Emergent Adverse Events (TEAEs), Acute Phase Reaction (APRs) and Treatment Emergent Serious Adverse Events (TESAEs) and Suspected Unexpected Serious Adverse Events (SUSARs) during the Open Label Extension Study.

    Endpoints will be summarized descriptively. Descriptive statistics for categorical variables will be frequencies and percentages. Descriptive statistics for continuous variables will be means, standard deviations, medians, minimums, and maximums.

    Time frame: Week 12

Secondary outcomes

  1. Change in "average pain" from baseline

    Assessed using an 11-point Numerical Rating Scale (NRS), with 0 representing no pain and 10 the worst possible pain.

    Time frame: Day 10, Weeks 3, 6, and 12

  2. At least a 30%, 50%, 70%, and 90% reduction of "average pain" from baseline

    Assessed using an 11-point Numerical Rating Scale (NRS), with 0 representing no pain and 10 the worst possible pain

    Time frame: Day 10, Weeks 3, 6, and 12

  3. Change from baseline in "pain now"

    Assessed using an 11-point Numerical Rating Scale (NRS), with 0 representing no pain and 10 the worst possible pain.

    Time frame: Day 10, Weeks 3, 6, and 12

  4. At least a 30%, 50%, 70%, and 90% reduction from baseline in "pain now"

    Assessed using an 11-point Numerical Scale (NRS) with 0 representing no pain and 10 the worst possible pain

    Time frame: Day 10, Weeks 3, 6, and 12

  5. Change from baseline in "worst pain"

    Assessed using an 11-point Numerical Rating Scale (NRS), with 0 representing no pain and 10 the worst possible pain.

    Time frame: Week 12

  6. At least a 30%, 50%, 70%, and 90% reduction from baseline of "worst pain"

    Assessed using an 11-point Numerical Rating Scale (NRS), with 0 representing no pain and 10 the worst possible pain.

    Time frame: Day 10 and Weeks 3, 6, and 12

  7. Change from baseline in the CRPS Severity Score (CSS)

    Assessed using the CRPS CSS, a 0-16 scale where higher scores denotes greater CRPS symptom severity and lower scores reflect milder symptoms.

    Time frame: Day 10, Weeks 3, 6, and 12

  8. Change from baseline to Week 12 in the CSS self-report (CSS-SR).

    Assessed using the CRPS CSS-SR, a 0-13 scale where higher scores denotes greater CRPS symptom severity and lower scores reflect milder symptoms.

    Time frame: Week 12

  9. Change from baseline in edema of affected limb

    Assessed using the "edema" 4-point numerical rating scale where 0 is no edema and 3 is severe edema.

    Time frame: Day 10, Weeks 3, 6, and 12

  10. Change from baseline in temperature (°C) of the affected limb vs contralateral limb.

    Assessment of 'temperature' is defined as the difference in temperature, measured in degrees Celsius (°C) using an infrared thermometer, between the affected limb and the contralateral limb.

    Time frame: Day 10 and Weeks 3, 6, and 12

  11. Patient Global Impression of Change (PGI-C) in CRPS-related health

    Assessed using a categorical scale of: "very much improved," "much improved," "minimally improved," "no change," "minimally worse," "much worse," and "very much worse," which will be mapped to numeric values of 1, 2, 3, 4, 5, 6, or 7 respectively.

    Time frame: Day 10 and Weeks 3, 6, and 12

  12. Clinician Global Impression of Change (CGI-C) in CRPS-related health

    Assessed using a categorical scale of: "very much improved," "much improved," "minimally improved," "no change," "minimally worse," "much worse," and "very much worse," which correspond to numeric values of 0, 1, 2, 3, 4, 5, 6 and 7 respectively.

    Time frame: Day 10 and Weeks 3, 6, and 12.

  13. Change from baseline in Patient Global Impression of Severity (PGI-S) in CRPS Severity.

    Assessed using a categorical scale of: "very much improved," "much improved," "minimally improved," "no change," "minimally worse," "much worse," and "very much worse," which correspond to numeric values of 0, 1, 2, 3, 4, 5, 6 and 7 respectively.

    Time frame: Day 10 and Weeks 3, 6, and 12

  14. Change from baseline in Short-Form McGill Pain Questionnaire 2 (SF-MPQ-2) (a) total pain score, (b) each of 4 domain scores, (c) single items.

    Assessed using a response to 22 descriptors rated on an 11-point numerical scale (NRS), capturing both neuropathic and non-neuropathic aspects. These descriptors are grouped into four core domains-Continuous Pain, Intermittent Pain, Neuropathic Pain, and Affective Descriptors-with domain scores calculated as the mean of items within each domain. The overall pain score is derived from the average of the 22 items. The complete scale runs from 0 to 10, where a higher score represents greater pain severity

    Time frame: Day 10 and Weeks 3, 6, and 12

  15. Moderate (at least 30%) and substantial (at least 50%) improvement from baseline in SF-MPQ-2 (a) total pain score, and (b) each of 4 domain scores.

    Assessed using a response to 22 descriptors rated on an 11-point numerical scale (NRS), capturing both neuropathic and non-neuropathic aspects. These descriptors are grouped into four core domains-Continuous Pain, Intermittent Pain, Neuropathic Pain, and Affective Descriptors-with domain scores calculated as the mean of items within each domain. The overall pain score is derived from the average of the 22 items. The complete scale runs from 0 to 10, where a higher score represents greater pain severity.

    Time frame: Day 10 and Weeks 3, 6, and 12

  16. Change from baseline in the 36-item Short Form 36 Item Health Survey [SF-36] (a) 8 domain scores and (b) 2 component summary scores.

    Assessment focuses on changes across eight domains: Physical Functioning, Role Limitations due to Physical Health, Role Limitations due to Emotional Problems, Energy/Fatigue, Emotional Well-being, and Social Functioning. Two summary scores-Physical Component Summary and Mental Component Summary-are derived. All domain scores are standardized to a 0-100 scale, with higher scores reflecting better health status

    Time frame: Day 10 and Weeks 3, 6, and 12

  17. Moderate (at least 30%) and substantial (at least 50%) improvement from baseline in the SF-36 (a) 8 domain scores and (b) 2 component summary scores.

    Assessment focuses on changes across eight domains: Physical Functioning, Role Limitations due to Physical Health, Role Limitations due to Emotional Problems, Energy/Fatigue, Emotional Well-being, and Social Functioning. Two summary scores-Physical Component Summary and Mental Component Summary-are derived. All domain scores are standardized to a 0-100 scale, with higher scores reflecting better health status

    Time frame: Day 10 and Weeks 3, 6, and 12

  18. Change from baseline in the Daily Sleep Interference Scale (DSIS) assessment on an 11-point NRS.

    Assessed using the 7-day average score on the 11-point Numerical Rating Scale (NRS), where 0 represents did not interfere with sleep and 10 represents completely interfered with sleep - unable to sleep due to CRPS pain

    Time frame: Day 10 and Weeks 3, 6, and 12

  19. Moderate (at least 30%) and substantial (at least 50%) improvement from baseline in the DSIS assessment.

    Assessed using the 7-day average score on the 11-point Numerical Rating Scale (NRS), where 0 represents did not interfere with sleep and 10 represents completely interfered with sleep - unable to sleep due to CRPS pain

    Time frame: Day 10 and Weeks 3, 6, and 12

07

Study locations

1 of 1 sites recruiting
  • Ambros Clinical Study Site
    Phoenix, Arizona 85032, United States
    Recruiting
08

References and documents

Related links

Individual participant data

Plan to share: Undecided

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2026 (actual). Primary completion is estimated for Dec 2028, 26 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2026
First posted
Oct 5, 2026
StartActual
Oct 13, 2026
Primary completionEst.
Dec 31, 2028
CompletionEst.
Feb 15, 2029
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 16, 2026
Sites
1 site added — first site in United States. Ambros Clinical Study Site is now Recruiting
Show site
  • Ambros Clinical Study Site · Phoenix, United States
across 2 updates, Oct 14, 2026 – Oct 16, 2026
Start date
Oct 15, 2026→Oct 13, 2026 (actual)
Oct 16, 2026
Registered
First appeared on the registry
Oct 5, 2026
Show all 3 updates
  1. Oct 16, 2026
    Not yet recruiting→Recruiting
    Ambros Clinical Study Site is now Recruiting
    Start date Oct 15, 2026→Oct 13, 2026 (now actual)
    + 1 other change: verification date
  2. Oct 14, 2026
    1 site added — first site in United States
    Show site
    • Ambros Clinical Study Site · Phoenix, United States
  3. Oct 5, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07857733
Lead sponsor
Ambros Therapeutics, Inc.
Responsible party
Sponsor
First posted
Oct 5, 2026
Start date
Oct 13, 2026
Primary completion
Dec 31, 2028 (estimated)
Completion
Feb 15, 2029 (estimated)
Last update
Oct 16, 2026

Study contacts

Medical Affairs Ambros Therapeutics
Contact
Medinfo@ambrostx.com
949-508-0173
Gail Cawkwell, MD, PhD
study director · Ambros Therapeutics, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Neridronic acid

Start the discussion